APC*E1317Q is a low-penetrance variant of the APC gene suggested as a risk for the development of colorectal adenomas and carcinomas. There is very little in the literature describing the molecular details of APC*E1317Q in tumor tissue. We provide information about the molecular genetics of 3 patients with APC*E1317Q. For 1 patient, we show linkage to a specific APC allele. We further show that loss of heterozygosity of the APC gene in tumors from carriers of the APC*E1317Q mutation may involve the mutated allele, not just the wild-type allele, suggesting the APC*E1317Q missense mutation may not be pathologically significant in the development of colorectal tumors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/PDM.0b013e3182830889 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Narrative Coherence of Autistic Children's Accounts of an Experienced Event in Response to Different Interviewer Prompts: A Longitudinal Study.
J Autism Dev Disord
December 2024
Department of Psychology, University of Cambridge, Cambridge, UK.
Purpose: This study explored the narrative coherence of the accounts of an experienced event produced by autistic and neurotypical children (ages 6-15 years) after delays of two weeks and two months.
Methods: The sample comprised 27 autistic children and 32 neurotypical peers, who were interviewed about the event using the Revised National Institute of Child Health and Human Development (NICHD) Investigative Interview Protocol. The study focused on assessing the narrative coherence of children's reports, emphasizing key story grammar elements and temporal features in their narratives.
A crucial active site network of titratable residues guides catalysis and NAD binding in human succinic semialdehyde dehydrogenase.
Protein Sci
January 2025
Department of Neuroscience, Biomedicine and Movement Sciences, Section of Biochemistry, University of Verona, Verona, Italy.
Human succinic semialdehyde dehydrogenase is a mitochondrial enzyme fundamental in the neurotransmitter γ-aminobutyric acid catabolism. It catalyzes the NAD-dependent oxidative degradation of its derivative, succinic semialdehyde, to succinic acid. Mutations in its gene lead to an inherited neurometabolic rare disease, succinic semialdehyde dehydrogenase deficiency, characterized by mental and developmental delay.
View Article and Find Full Text PDFDiscovery of a Chimeric Polyketide Family as Cancer Immunogenic Chemotherapeutic Leads.
J Am Chem Soc
December 2024
Department of Chemistry and Biochemistry, University of South Carolina, Columbia, South Carolina 29208, United States.
Discovery of cancer immunogenic chemotherapeutics represents an emerging, highly promising direction for cancer treatment that uses a chemical drug to achieve the efficacy of both chemotherapy and immunotherapy. Herein, we report a high-throughput screening platform and the subsequent discovery of a new class of cancer immunogenic chemotherapeutic leads. Our platform integrates informatics-based activity metabolomics for the rapid identification of microbial natural products with both novel structures and potent activities.
View Article and Find Full Text PDFGenetic architecture of Multiple Myeloma and its prognostic implications - An updated review.
Malays J Pathol
December 2024
Universiti Sains Malaysia, School of Medical Sciences, Human Genome Centre, Health Campus, Kelantan, Malaysia.
Multiple myeloma (MM), a clonal B-cell neoplasia, is an incurable and heterogeneous disease where survival ranges from a few months to more than 10 years. The clinical heterogeneity of MM arises from multiple genomic events that result in tumour development and progression. Recurring genomic abnormalities including cytogenetic abnormalities, gene mutations and abnormal gene expression profiles in myeloma cells have a strong prognostic power.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!